8,288 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Transamerica Financial Advisors LLC

Transamerica Financial Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, HoldingsChannel reports. The firm bought 8,288 shares of the biopharmaceutical company’s stock, valued at approximately $2,495,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the last quarter. Golden State Wealth Management LLC raised its position in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Coldstream Capital Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 38 shares during the last quarter. Atlantic Union Bankshares Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 20.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 40 shares during the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 3.3% in the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 40 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the company. JPMorgan Chase & Co. cut their price objective on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Citigroup decreased their target price on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Oppenheimer cut their price target on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Finally, Barclays decreased their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $386.14.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.4%

Shares of NASDAQ ALNY opened at $239.00 on Thursday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55. The business has a 50-day moving average price of $264.27 and a two-hundred day moving average price of $294.77. The firm has a market capitalization of $31.98 billion, a PE ratio of 44.42 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) EPS. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.